WEBULL

Eurofins Scientific (ENXTPA:ERF) Stock Margins Improve As Turnaround Narrative Gains Support

Simply Wall St · 2d ago

Eurofins Scientific (ENXTPA:ERF) has just posted H1 2026 results with revenue of €3.7b and basic EPS of €1.55, setting the tone for a set of numbers that investors can now weigh against both recent momentum and longer term trends. The company has seen revenue move from €3.6b and basic EPS of €1.20 in H1 2025 to €3.7b and €1.55 in H1 2026. Trailing twelve month figures now stand at €7.4b of revenue and basic EPS of €2.66, framing a clear earnings season snapshot for holders tracking the story. With net profit margins having improved over the last year, the latest release gives investors fresh data on how sustainable that profitability profile might be.

See our full analysis for Eurofins Scientific.

With the headline numbers on the table, the next step is to see how these results line up against the key narratives around Eurofins Scientific, highlighting where recent performance supports the story and where it starts to push back against it.

See what the community is saying about Eurofins Scientific

ENXTPA:ERF Revenue & Expenses Breakdown as at Jul 2026
ENXTPA:ERF Revenue & Expenses Breakdown as at Jul 2026

Margins and EPS Point to 23.3% Earnings Growth

  • Over the last 12 months, Eurofins Scientific generated €7.4b of revenue and €469.9 million of net income, with earnings up 23.3% year over year and net profit margin at 6.4% versus 5.3% a year earlier.
  • What stands out for the bullish view is that this margin shift and the move from H1 2025 net income of €219.0 million to €272.8 million in H1 2026 line up with the idea that Eurofins' investments in digitalization and infrastructure are already feeding through to efficiency and profit growth.
    • Bullish analysts expect earnings to grow around 17.5% per year from here and see room for margins to keep improving, which sits alongside the recent 23.3% trailing earnings lift and higher net margin.
    • At the same time, the five year trend, where earnings declined about 16.9% per year, highlights that the bullish case is leaning heavily on this recent turnaround being sustained rather than a short blip against a tougher longer term record.

Bulls argue that this mix of higher recent margins and earnings growth could be the early stage of the efficiency story they expect to continue, and they set out their full case in the 🐂 Eurofins Scientific Bull Case.

Short Term Momentum vs Five Year Earnings Drag

  • On a trailing 12 month view, earnings have grown 23.3%, yet over the last five years they declined about 16.9% per year, so the recent improvement sits against a much weaker multi year backdrop.
  • Bears focus on this longer record, arguing that expansion and acquisitions can be capital intensive and may compress margins over time, and the five year decline in earnings backs up concerns that not every growth initiative has translated into durable profit gains.
    • The current margin of 6.4% compared to 5.3% a year earlier helps to counter the idea that profitability is stuck under pressure, but it does not erase the multi year earnings drop that cautious investors highlight.
    • With biopharma and genomics mentioned as structurally challenging areas in the cautious narrative, the fact that trailing revenue of €7.4b is only modestly above the €7.1b to €7.3b levels seen in the prior periods supports the argument that growth across all segments has not been smooth.

Skeptics suggest that the recent earnings lift may not fully resolve concerns about acquisition risks and segment headwinds, and they outline that cautious stance in the 🐻 Eurofins Scientific Bear Case.

Valuation Gap: P/E of 24.5x and DCF Fair Value

  • Eurofins Scientific trades on a P/E of 24.5x against a reported Global Life Sciences industry average of 36.6x and peer average of 30.1x, and a DCF fair value of €123.47 compares with the current share price of €66.40.
  • Consensus narrative supporters point to this valuation gap as a potential upside driver if the expected improvement in margins and earnings plays out, but also flag that high debt levels and integration costs could limit how quickly the share price moves toward the €72.10 analyst target.
    • The combination of a 6.4% net margin and €469.9 million of trailing net income suggests the business is currently profitable, and analysts are forecasting around 5.9% annual revenue growth and margin expansion over the next few years.
    • However, with the balance sheet described as carrying elevated debt, any setback in converting that revenue and margin outlook into cash flow would make it harder for the stock to close the gap between €66.40, the €72.10 analyst target and the higher DCF fair value.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Eurofins Scientific on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With Eurofins Scientific showing both reasons for optimism and areas that raise questions, this is a good moment to move quickly and test the numbers against your own expectations, including the balance between 4 key rewards and 1 important warning sign.

See What Else Is Out There

Eurofins Scientific's recent uplift in margins and earnings still sits beside a weaker five year earnings record and concerns around elevated debt and acquisition risks.

If that mix of balance sheet pressure and uneven long term progress feels uncomfortable, use the solid balance sheet and fundamentals stocks screener (419 results) to quickly focus on companies where financial strength is front and center.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.